检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]苏州大学附属中国人民解放军第二炮兵总医院泌尿外科,北京市100088
出 处:《热带病与寄生虫学》2014年第2期96-100,共5页Journal of Tropical Diseases and Parasitology
摘 要:目的利用Meta分析评价头孢曲松与大观霉素治疗单纯性淋病的疗效。方法检索Cochrane图书馆,Pubmed数据库,中国生物医学文献数据库,CNKI数据库,VIP数据库,万方数据库,纳入头孢曲松与大观霉素对比治疗单纯性淋病的随机对照试验(RCT),并进行方法学质量评价。采用RevMan5.2软件进行统计分析,并进行敏感性分析。结果 6篇RCT文献纳入本项研究,累计病例789例。Meta分析结果显示:头孢曲松在提高痊愈率[OR.1.18;95%CI(1.06,3.34),P<0.051和总有效率方面[OR3.96;95%CI(1.29,12.1 8),P<0.05]差异具有统计学意义,而在细菌清除率[OR3.17;95%CI(0.32,31.09),P>0.05]和不良反应[OR0.39;95%CI(0.11,1.36),P>0.05]方面则无明显差异。结论头孢曲松在治疗单纯性淋病中疗效确切,是治疗单纯性淋病的有效方法。Objective To evaluate the efficacy and safety of rocephin versus rpectinomycin for uncomplicated gonorrhea by Meta-analysis . Methods The studies involving randomized controlled trials (RCTs) on ceftriaxone (rocephin) versus spectinomycin for uncomplicated gonorrhea were collected from the database, such as the Cochrane Library, Pubmed, CBMdisc, CNKI, VIP and Wanfang. After the necessary methodological quality evaluation of the selected studies, assessment of publication bias and sensitivity analysis, the statistic analysis was conducted by the software RevMan5.2. Results Six eligible reports were identified in this study, including accumulative total 789 cases. The Meta-analysis results showed rocephin in the treatment of uncomplicated gonorrhea had higher effectiveness and recovery than the spectinomycin group(P〈0.05), which could increase the cure rate [OR1.18;95%CI(1.06,3.34),P〈0.05] and the total effective rate [OR3.96;95%CI(1.29, 12.18), P〈0.05],but there were no significant difference among bacterial eradication rate and incidence of adverse reactions. Conclusion The ceftriaxone (rocephin) showed definite curative effect in the treatment of uncomplicated gonorrhea.
关 键 词:头孢曲松(罗氏芬) 大观霉素 壮观霉素 循证医学 META分析
分 类 号:R195.1[医药卫生—卫生统计学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.49